UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, D.C. 20549


                                   FORM 10 QSB

            Quarterly Report Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934


            For the quarterly period ended           March 31,2001
            Commission file Number                   000-25019


                                 PVAXX CORPORATION
                       (Formerly Oak Brook Capital IV, Inc.)

              (Exact Name of Registrant as Specified in its Charter)


                                     COLORADO
                  (State or Other Jurisdiction of Incorporation)



               000-25019                                05-0499528
        (Commission File Number)         (I.R.S. Employer Identification Number)



             237 Park Avenue
             New York                                   NY 10017
(Address of Principal Executive Offices)               (Zip Code)



                                 (212) 551 1494
              (Registrant's Telephone Number, Including Area Code)


<PAGE>

Indicate by check mark whether the registrant (1) has filed
all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to
file such reports), and (2) has been subject to such filing
requirements for the past 90 days.

                         YES [X]        NO [  ]

Indicate the number of shares outstanding of each of the
issuer's classes of common stock, as of the latest practical
date:

Common Stock, No Par Value - 21,322,800 shares as of
March 31,2001.


<PAGE>  1

                           FORWARD-LOOKING INFORMATION

THIS FORM 10QSB AND OTHER STATEMENTS ISSUED OR MADE FROM TIME TO TIME BY
PVAXX CORPORATION INCORPORATED OR ITS REPRESENTATIVES CONTAIN STATEMENTS
WHICH MAY CONSTITUTE "FORWARD-LOOKING STATEMENTS" WITHIN THE MEANING OF
THE SECURITIES ACT OF 1933 AND THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED BY THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. FIFTEEN
U.S.C.A. SECTIONS 77Z-2 AND 78U-5 (SUPP. 1996). THOSE STATEMENTS INCLUDE
STATEMENTS REGARDING THE INTENT, BELIEF OR CURRENT EXPECTATIONS OF PVAXX
CORPORATION AND MEMBERS OF ITS MANAGEMENT TEAM AS WELL AS THE ASSUMPTIONS
ON WHICH SUCH STATEMENTS ARE BASED.

PROSPECTIVE INVESTORS ARE CAUTIONED THAT ANY SUCH FORWARD-LOOKING STATEMENTS
ARE NOT GUARANTEES OF FUTURE PERFORMANCE AND INVOLVE RISKS AND UNCERTAINTIES,
AND THAT ACTUAL RESULTS MAY DIFFER MATERIALLY FROM THOSE CONTEMPLATED BY SUCH
FORWARD-LOOKING STATEMENTS. IMPORTANT FACTORS CURRENTLY KNOWN TO MANAGEMENT
THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN FORWARD-
LOOKING STATEMENTS ARE SET FORTH IN THE SAFE HARBOR COMPLIANCE STATEMENT FOR
FORWARD-LOOKING STATEMENTS INCLUDED AS EXHIBIT 99.1 TO THIS FORM 10QSB AND
ARE HEREBY INCORPORATED HEREIN BY REFERENCE. THE COMPANY UNDERTAKES
NO OBLIGATION TO UPDATE OR REVISE FORWARD-LOOKING STATEMENTS TO REFLECT
CHANGED ASSUMPTIONS, THE OCCURRENCE OF UNANTICIPATED EVENTS OR CHANGES TO
FUTURE OPERATING RESULTS OVER TIME.


ITEM 1.  FINANCIAL STATEMENTS

<PAGE>  F-1

                PVAXX CORPORATION (Formerly Oak Brook Capital IV)
                          (A Development Stage Company)
                        CONSOLIDATED FINANCIAL STATEMENTS
                            March 31, 2001 (Unaudited)

Index to Financial Statements                                        F-1
Accountant's Review Report                                           F-2
Consolidated Balance Sheets                                          F-3
Consolidated Statements of Operations                                F-4
Consolidated Statements of Changes in Stockholders' Equity           F-5
Consolidated Statements of Cash Flows                                F-6
Notes to Financial Statements                                        F-7

<PAGE>  F-2

Accountant's Review Report

To the Board of Directors and Stockholders of PVAXX Corporation

We have reviewed the accompanying consolidated balance sheet of PVAXX
Corporation and Subsidiaries as of March 31, 2001 and the related
consolidated statements of operations, changes in stockholders'
equity and cash flows for the three and nine month periods ended
March 31, 2001, and the cumulative totals for development stage
operations from March 16,2000 (inception) through March 31,2001, in
accordance with Statements on Standards for Accounting and Review
Services issued by the American Institute of Certified Public
Accountants. All information included in these financial statements
is the representation of management of PVAXX Corporation.

A review consists principally of inquiries of Company's personnel
and analytical procedures applied to financial data. It is
substantially less in scope than an audit conducted in
accordance with auditing standards generally accepted in the United
States of America, the objective of which is the expression of an
opinion regarding the financial statements taken as a whole.
Accordingly, we do not express such an opinion.

Based on our review, we are not aware of any material
modifications that should be made to the accompanying financial
statements in order for them to be in conformity with accounting
principles generally accepted in the United States of America.

As discussed in Note #1 to the financial statements, the
Company and all of its subsidiaries are in a development
stage, and have yet to realize any substantial revenue. This
raises substantial doubt about the company's ability
to continue as a going concern. Management's plan in regard
to these matters is discussed in Note #1. The accompanying
financial statements do not include any adjustments to the
financial statements that might be necessary should the
Company be unable to continue as a going concern.


PKF
Nottingham, UK
August 23, 2001



 <PAGE>  F-3
                  PVAXX CORPORATION (Formerly Oak Brook Capital IV)
                             (A Development Stage Company)
                              CONSOLIDATED BALANCE SHEETS

<TABLE>
<CAPTION>

                                  ASSETS
                                  ------

                                                      March 31,2001   June 30,2000
                                                        (Unaudited)      (Audited)
<S>                                                   <C>             <C>

CURRENT ASSETS:
     Cash and cash equivalents                          $     8,643       118,631
     Restricted cash and cash equivalents (Note 5 )         299,970       299,970
     Accounts receivable                                      1,530            -
     VAT (tax) refund receivable                             21,330        22,988
     Inventories                                             19,257            -
     Prepaid expenses                                        18,746        46,659
                                                         ----------    ----------
            Total current assets                        $   369,476   $   488,248

PROPERTY, PLANT and EQUIPMENT: (Note 9)
     Leasehold property improvements                    $    35,206             -
     Machinery & equipment                                  656,313       601,148
     Office furniture & equipment                            58,253        55,521
     Motor vehicles                                          15,044        12,775
     Less:  accumulated depreciation                       (135,049)      (20,216)
                                                         ----------     ---------
            Net property, plant & equipment             $   629,767    $  649,228

INTANGIBLE ASSETS: (Note 2)
     Patents & trademarks                               $   117,643    $   68,018

OTHER ASSETS:
     Deposits                                           $     4,349    $    4,349
                                                         ----------     ---------
     Total assets                                       $ 1,121,235    $1,209,843
                                                         ----------     ---------

                   LIABILITIES AND SHAREHOLDERS' EQUITY
                   ------------------------------------

CURRENT LIABILITIES:
     Accounts Payable                                   $   103,316       107,942
     Capital lease obligations (Note 8)                       2,749         2,937
     Capital lease obligations to related
             parties (Note 8)                               125,115       133,655
     Loans payable to related parties                     1,195,373       173,088
     Accrued interest - related parties                      63,731             -
     Accrued wages - officers                               653,000       180,000
     Other accrued liabilities                                6,115        19,163
                                                          ---------     ---------
          Total current liabilities                     $ 2,149,399   $   616,785

LONG TERM LIABILITIES:
     Capital lease obligations(Note 8)                  $     1,833         4,160
     Capital lease obligations to related
             parties (Note 8)                               348,800       472,849
                                                          ---------     ---------
          Total long term liabilities                   $   350,633   $   477,009
                                                          ---------     ---------
     Total liabilities                                  $ 2,500,032   $ 1,093,794

SHAREHOLDERS' EQUITY:
     Preferred stock - no par value, 0%,
      Non-cumulative, non-participating, convertible
      10,000,000 shares authorized,
      issued and outstanding                            $  100,000    $   100,000
     Common stock - no par value,
      40,000,000 shares authorized
      21,322,800 shares issued and outstanding
      of which 90,000 shares are in escrow (Note 5)        204,200        204,200
     Additional Paid-in Capital                            160,956        160,956
     Deficit accumulated during the development stage   (1,843,953)      (349,107)
                                                        ----------      ---------
     Total equity                                      $(1,378,797)   $   116,049
                                                        ----------      ---------
     Total liabilities and equity                      $ 1,121,235    $ 1,209,843
                                                        ----------      ---------

The accompanying notes are an integral part of these financial statements.

</TABLE>

<PAGE> F-4

                  PVAXX CORPORATION (Formerly Oak Brook Capital IV)
                            (A Development Stage Company)
                       CONSOLIDATED STATEMENTS of OPERATIONS
      For the three and nine months ended March 31, 2001 and from March 16, 2000
              (Inception of accounting acquirer) through March 31, 2001

<TABLE>
<CAPTION>

                                                        2001           2001           2000  From Inception
                                                    3 months       9 months       March 16  (March 16,2000)
                                                       ended          ended     (inception) thru' March 31
                                                    March 31       March 31     to June 30            2001
                                                  (Unaudited)    (Unaudited)      (Audited)     (Unaudited)

<S>                                             <C>            <C>            <C>             <C>
SALES                                           $      1,257   $      3,699   $          -    $      3,699
                                                 -----------    -----------    -----------     -----------
   Cost of Goods Sold and
        Other Operating Charges                 $        (58)  $          -   $          -    $          -
   Research & Development Costs                      272,632        522,136        135,622         657,758
   Selling, General &
        Administrative Costs                        (115,050)       846,860        200,414       1,047,274
   Depreciation & Amortization                        (1,938)       114,833         19,151         133,984
                                                ------------   ------------   ------------    ------------
      Total Costs                               $    155,586   $  1,483,829   $    355,187    $  1,839,016
                                                 -----------   ------------   ------------    ------------

Operating (loss)                                $   (154,329)  $ (1,480,130)  $   (355,187)   $ (1,835,317)
OTHER INCOME / (EXPENSE)
   Interest                                          (23,036)       (78,067)        (3,003)        (81,070)
   Currency re-measurement                            63,351         63,351          9,083          72,434
                                                 -----------   ------------   ------------    ------------
Net Operating Loss)                             $   (114,014)  $ (1,494,846)  $   (349,107)   $ (1,843,953)

INCOME TAXES                                               -              -              -               -
                                                ------------   ------------   ------------    ------------
Net loss accumulated during the
 development stage                              $   (114,014)  $ (1,494,846)  $   (349,107)   $ (1,843,953)
                                                ------------   ------------   ------------    ------------
PER SHARE INFORMATION (Note 7)
  Weighted average number of
  common shares outstanding                       21,322,800     21,322,800     20,605,111      21,139,477
                                                ------------   ------------   ------------    ------------
Basic & Diluted (loss) per share                $      (0.01)  $      (0.07)  $      (0.02)   $      (0.09)
                                                ------------   ------------   ------------    ------------

  The accompanying notes are an integral part of these financial statements.

</TABLE>

<PAGE> F-5

                 PVAXX CORPORATION (Formerly Oak Brook Capital IV)
                           (A Development Stage Company)
             CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS EQUITY

<TABLE>
<CAPTION>

                                     Shares Issued
                                 ----------------------
                                                                        Additional   Retained     Equity
                       Common     Preferred    Common       Preferred    Paid-in     Earnings
                        Stock      Stock        Stock        Stock        Capital
                     ---------- -----------  -----------  -----------  ------------  ---------   ----------
<S>                 <C>         <C>          <C>          <C>          <C>           <C>         <C>
Acquisition of
subsidiary
corporations by
PVAXX

 Issuance of stock
 to founder
 (March 29,2000)     20,000,000  10,000,000  $  200,000  $   100,000     $ (291,386) $        -  $    8,614

Buy back of common
stock to facilitate
private placements
(Note 2)               (134,832)          -      (1,348)           -          1,348           -           -

Issuance of common
stock for cash
restricted by
investor
(April 4,2000)           90,000           -         900            -       299,070            -     299,970

Reverse acquisition
of Oak Brook Capital
IV (May 19,2000)      1,322,800           -       4,200            -        (4,200)           -           -

Issuance of common
stock to various
persons for cash
(May 30,2000)            44,832           -         448            -       156,124            -     156,572

Net loss for the period       -           -           -            -             -     (349,107)   (349,107)
                     ----------  ----------  ----------  -----------    ----------  -----------   ---------

Balance June 30,2000
 (Audited)           21,322,800  10,000,000     204,200      100,000       160,956     (349,107)    116,049

Net loss for the period
 ended March 31,2001          -           -           -            -             -   (1,494,846) (1,494,846)
                     ----------  ----------  ----------  -----------    ----------  -----------  ----------

Balance March 31,2001
(Unaudited)          21,322,800  10,000,000  $  204,200  $   100,000    $  160,956  $(1,843,953)$(1,378,797)
                     ----------  ----------  ----------  -----------    ----------  -----------  -----------


The accompanying notes are an integral part of these financial statements.

</TABLE>

<PAGE> F-6

                  PVAXX CORPORATION (Formerly Oak Brook Capital IV)
                            (A Development Stage Company)
                        CONSOLIDATED STATEMENTS OF CASH FLOWS
                For the three and nine months ended March 31,2001 and
       from  March 16, 2000(Inception of accounting acquirer) to March 31,2001
<TABLE>
<CAPTION>


                                                           2001          2001          2000  From Inception
                                                       3 months      9 months      March 16  (March 16,2000)
                                                          ended         ended    (inception) thru' March 31
                                                       March 31      March 31    to June 30            2001
                                                     (Unaudited)   (Unaudited)     (Audited)     (Unaudited)
<S>                                               <C>            <C>            <C>           <C>
CASH (USED) IN OPERATING ACTIVITIES:
  Net Loss                                        $    (114,014) $ (1,494,846)  $  (349,107)   $(1,843,953)
  Adjustments to reconcile net loss to net cash
   provided by / (used in) operating activities:
    Depreciation & amortization                   $      (1,938) $    114,833   $    19,151    $   133,984
    Currency re-measurement adjustment on capital
    lease obligations                                   (24,835)     (36,575)        (4,764)       (41,339)
    (Increase) in accounts receivable                    (1,530)      (1,530)             -         (1,530)
    Decrease/(Increase) in VAT taxes receivable           1,415        1,658        (21,685)       (20,027)
    (Increase)/Decrease in inventories                   56,004      (19,257)             -        (19,257)
    Decrease/(Increase) in prepaid expenses              (2,554)      27,913        (46,659)       (18,746)
    (Increase) in other assets                                -            -         (4,349)        (4,349)
    Increase/(Decrease) in accounts payable             (19,311)      (4,626)       107,942        103,316
    Increase/(Decrease) in accrued interest             (69,843)      63,731              -         63,731
    Increase /(Decrease) in accrued liabilities         (25,178)     (13,048)         4,109         (8,939)
    Increase in accrued officer wages                   153,065      473,000        180,000        653,000
                                                   ------------- -------------   -----------   ------------
 Net cash provided by/(used in) operating
  activities                                       $    (48,719)  $ (888,747)    $ (115,362)   $(1,004,109)

INVESTING ACTIVITIES:
    Purchase of equipment                               (36,699)     (95,372)       (23,361)      (118,733)
    Acquisition of patents & trademarks                 (51,243)     (49,625)             -        (49,625)
                                                   -------------- ------------   -----------   ------------
 Cash (used in) investing activities               $    (87,942)  $ (144,997)    $  (23,361)   $  (168,358)

CASH PROVIDED BY FINANCING ACTIVITIES:
    Proceeds from sale of common stock                        -            -        456,542        456,542
    Cash restricted by investor                               -            -       (299,970)      (299,970)
    Increase in loans by related party                  169,742    1,022,285        123,958      1,146,243
    Capital element of capital lease payments           (32,798)     (98,528)       (23,176)      (121,705)
                                                   -------------- ------------   -----------   ------------
 Cash provided by financing activities             $    136,944   $  923,757     $  257,354    $ 1,181,110
                                                   -------------- ------------   -----------   ------------

Increase/(Decrease) Cash and Cash Equivalents               283     (109,988)       118,631          8,643
Cash at beginning of period                               8,360      118,631              0              0
                                                   -------------- ------------   -----------   ------------
Cash at end of period                              $      8,643   $    8,643     $  118,631     $    8,643
                                                   -------------- ------------   -----------   ------------

Supplemental information:
    Interest paid                                  $      4,607   $   13,837     $    3,003     $   16,840
    Income tax paid                                           -            -              -              -
Non-cash transactions
  Acquisition of plant & equipment on capital leases
                                                   $          -   $        -     $ (646,083)    $ (646,083)
  Acquisition of patents for stock                 $          -   $        -     $  (68,018)    $  (68,018)
  Capital equipment leases                         $          -   $        -     $  641,541     $  641,541


The accompanying notes are an integral part of these financial statements.

</TABLE>

<PAGE>  F-7

                  PVAXX CORPORATION (Formerly Oak Brook Capital IV)
                            (A Development Stage Company)
                            NOTES TO FINANCIAL STATEMENTS
                                  AS OF MARCH 31,2001

NOTE 1 - NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

History of the Reporting Entity

PVAXX  Corporation, formed in Florida on March 16, 2000, is the parent
corporation of PVAXX Technologies Ltd., PVAXX Research & Development Ltd.
and PVAXX (Europe) Ltd. PVAXX Corporation acquired the net
business assets of PVAXX Technologies Ltd. and PVAXX Research &
Development Ltd. in exchange for 10,000,000 shares of its Preferred
and 20,000,000 shares of its Common stock. The net business assets
consisted of the costs of two patent applications described below,
current liabilities, and a leased vehicle. This transaction was accounted
for as a combination of entities under common control and was recorded
at the historical cost of the assets and liabilities. The PVAXX
companies were owned and controlled by a company owned and
controlled by the acquiring Company's President and Chairman of the
Board of Directors. The only activities of any of these companies to
date have been development stage activities.

The role of each of the subsidiary companies is as follows:

* PVAXX Technologies Ltd. is the holder of unlimited rights to
    manufacture, process, and sell poly vinyl alcohol products
    governed by patents issued under International Publication
    Numbers WO 98/26911 on June 25,1998 and WO 00/12615 on March
    9,2000.

* PVAXX Research and Development Ltd. performs research
   into product improvements and applications. Doing business
   as PVAXX Engineering, it produces machines forming the product
   into pellets, which are then sold to converters. Under the
   trade style PVAXX "SoftCap" Systems it manufactures and sells
   capsule making machinery.

* PVAXX (Europe) Ltd. is a dormant company.

Oak Brook Capital IV, (Oakbrook IV) was formed in May 1998 in
Colorado, with 40,000,000 shares of common and 10,000,000 shares
of preferred stock authorized.  It was registered with the SEC
as one of a series of blank check companies seeking a business
combination with an operating company. On May 19,2000,
Oakbrook IV entered into a share exchange agreement with PVAXX
Corporation, a development stage company. The transaction is
reported herein as a reverse acquisition with PVAXX as the
accounting acquirer and Oakbrook IV as the legal survivor.
At the time of the acquisition Oakbrook IV had 1,322,800 shares
outstanding, had no assets, had recognized no revenue, and had
incurred expenses of $4,200.

In conjunction with the reverse acquisition, Oakbrook IV changed
its name to PVAXX Corporation, and the newly named PVAXX
Corporation and all of the subsidiaries have changed their
respective fiscal year-ends to June 30.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements
have been prepared in accordance with generally accepted accounting
principles for interim financial information and with the instructions
to Form 10-QSB and Item 310(b) of Regulations SB. Accordingly, they do
not include all of the information and footnotes required by generally
accepted accounting principles for complete financial statements. In the
opinion of management, all adjustments (consisting of normal recurring
accruals) considered necessary for a fair presentation have been included.
Operating results for the three and nine month periods ended March 31,2001,
are not necessarily indicative of the results that may be expected for the
year ended June 30,2001.

The balance sheet at June 30,2000 and the statement
of operations for the period March 16,2000 (inception) to June 30,2000, have
been derived from the audited financial statements at that date but does not
include all of the information and footnotes required by generally accepted
accounting principles for complete financial statements.

For further information, refer to the consolidated financial statements and
footnotes thereto included in the Registrant Company and Subsidiaries annual
report on Form 10-KSB for the period ended June 30,2000.

These financial statements represent the historical operations of
PVAXX from March 29,2000, the date the Florida group was
formed, and includes the reverse acquisition of the Colorado
corporation, Oak Brook Capital IV.

The statements have been prepared on a going concern basis.
The ability of the Company to emerge from the development stage
and to develop into a going concern is dependent on the success
of the Company in negotiating long-term revenue contracts
and acquiring additional equity capital. However, there can
be no assurance that the Company will be successful in
accomplishing its objectives. The financial statements do
not include any adjustments that might be necessary should the
Company be unable to continue as a going concern.

The Company is addressing the substantial doubt about its
ability to continue as a going concern through the deferral
of cash payments to the principal shareholders, through the
negotiation of anticipated private placements with additional
investors, and by taking steps to register shares for sale
on the public market, in order to generate additional working
capital for the Company to expand its operations and to
bring its product to market. In addition, certain of the
Company's officers and shareholders have agreed that they
will advance to the Company some additional funds that the
Company needs for operating capital. Although of the
balance sheet date, March 31,2001, the Company had not
entered into any significant revenue-producing contracts,
several successful field tests of various products have
been conducted, and management expects to have successfully
negotiated several contracts before the end of this calendar
year.

Foreign Currency Translation and Transactions

The U.S. dollar is the "functional" currency of most of the
Company's worldwide operations. The financial position
and results of operations of the Company's foreign
subsidiaries are determined using the U.S. dollar as
the functional currency. Assets and liabilities of these
subsidiaries are translated at the exchange rate in effect
as of the balance sheet date with the exception of fixed
assets, patents and inventories which are translated at the
exchange applicable on the date of acquisition. Income
statement accounts are translated at the average rate of
exchange prevailing during the period. Exchange gains
and losses arising from the re-measurement of foreign
currency denominated monetary assets and liabilities are
included in income in the period in which they occur.

Use of Estimates

The process of preparing financial statements in
conformity with generally accepted accounting principles
requires management to make estimates and assumptions
that affect the reporting of amounts of assets and
liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements
and the reported amounts of revenues and expenses
during the reporting period. Actual results could
differ from these estimates. These Interim Financial
Statements include all adjustments which in the opinion
of management are necessary in order to make the financial
statements not misleading.

Cost accruals were overestimated at December 31,2000 by
$390,000. The operating loss for the quarter ended
March 31,2001 is beneficially affected by the inclusion
of an adjustment to correct this error.

Cash and Cash Equivalents

Highly liquid assets with a maturity date of  three
(3) months or less from the date of acquisition are
treated as cash or cash equivalents.

Property, Plant and Equipment

Property, plant and equipment is stated at cost less
accumulated depreciation. Depreciation is computed
using the straight-line method over the estimated
useful lives of the assets. Estimated useful lives
of property, plant and equipment are as follows:

              Machinery & equipment        3 to 7 years
              Office furniture & equipment 3 to 5 years
              Motor vehicles               4 years

The amortization of leasehold property improvements is
based on the shorter of the primary lease term or the
life of the improvement.

Betterments and large renewals, which extend the life
of an asset, are capitalized whereas maintenance and
repairs and small renewals are expensed as incurred.

Inventory

Inventories consist of raw materials and are stated at
the lower of cost (first-in, first-out) or market value.

Value Added Tax (VAT)

The United Kingdom subsidiaries are required to receive
a Value Added Tax from appropriate customers and are
required to pay a Value Added Tax (VAT) on purchases
made from certain vendors. The net amount of the tax
is either payable to, or receivable from, the Government.
The Company currently receives a tax refund for the VAT
paid to various vendors.

Intangibles

The patents were acquired from a related party in
exchange for stock in the PVAXX group of companies.
Intangible assets such as patents or other intellectual
property are recorded at cost. These costs are the fees
and expenses of patent and trademark attorneys and
agents incurred in applying for such protection. Such
intangible assets are amortized over their estimated
useful lives based on the nature of the item. The
Company will begin amortizing its patents when it emerges
from the development stage.

In accordance with Statement of Accounting Standards
no. 121, "Accounting for the Impairment of Long-Lived
Assets and for Long-Lived Assets to be Disposed of",
intangibles are evaluated for impairment when events or
changes in circumstances  indicate that the carrying
amounts of the assets may not be recoverable through
the estimated undiscounted future cash flows resulting
from the use of these assets. When any such impairment
exists, the related assets are written down to fair value.

The Company has generated a small amount of revenue
relating to its patents due to the fact that its
operations are in the development stage. Although
there is substantial doubt about the Company's
ability to continue as a going concern as described
under "Basis of presentation" above, the Company
has just acquired the patents and it is actively
engaged in promoting and developing this technology.

At this time there are no events and conditions
that exist to indicate that the asset may be impaired.
However, should the Company's efforts to negotiate
long-term revenue contracts for its products be
unsuccessful, the Company may realize an impairment
loss on the write-down of the patent to its fair value.

Research and Development

Research and development expenditure is written off
in the period in which the expenditure is incurred.

Income Taxes

The Company uses the asset and liability method
as identified in Statement of Accounting Standards
no. 109, "Accounting for Income Taxes". The
consolidated  Company has a net operating loss
carry-forward (NOL) of $(1,843,953) available
to future periods due to losses generated since
its inception through March 31, 2001. The net
operating losses and credits expire at various
dates through 2020. This NOL would result in the
recording of a tax asset based on application of
appropriate UK and US tax rates if offsetting
profits were anticipated. Because the Company
and its subsidiaries are in the development
stages, there is no assurance that future
operations will generate a profit or income,
therefore the Company recognizes a valuation
adjustment which completely offsets the deferred
tax asset related to the net operating loss
carry-forward.

Convertible Preferred Stock

The Company issued convertible preferred stock
relating to the formation transaction discussed
above and in Note 2. The preferred stock does
not have voting rights, and is non-cumulative,
non-participating and has preference up to its
par value upon liquidation. The stock may be
converted 1 for 1 for common stock at the
discretion of holder.

Revenue Recognition

The Company recognizes revenue when the
earnings process is complete. This generally
occurs when products are shipped to the customer
in accordance with the terms of the agreement,
title and risk of loss have transferred,
collectibility is probable, and pricing is
fixed and determinable.


NOTE 2 - RELATED PARTY TRANSACTIONS

As discussed in Note 1, the Company effectively
acquired PVAXX Technologies Ltd. and PVAXX Research
and Development Ltd. from a company owned and controlled
by the President and Chairman of the Board of
Directors of PVAXX Corporation. The ultimate
consideration for the transaction is the 10,000,000
shares of Preferred stock and 20,000,000 shares
of Common stock held by the majority shareholder
and others whose PVAXX Florida corporation shares were
exchanged.

The share exchange agreement between Oak Brook
Capital IV and the PVAXX Florida corporation restricted
the issue of further stock pending the effective date
of completion. In order to allow private investors,
who wished to invest in the Company, to purchase
stock, the Company's majority shareholder agreed to
surrender the number of shares required (134,832) to
satisfy these demands. The Company did not pay the
majority shareholder for these shares, therefore, the
Company plans to issue new shares before March 31,2002
to the majority shareholder for nil consideration to
compensate it for the shares that it surrendered for this
purpose.

Through March 31,2001, the major shareholder has
advanced $1,195,373 to the companies. The amounts
advanced are repayable on demand and an interest
rate of 8% has been assumed. The Company has accrued
interest of $63,731 relating to these advances.

The patent rights owned by PVAXX Technologies Ltd.,
were developed by and acquired from a company owned by
the President and majority shareholder and are carried
at their original historical cost of $68,018 plus
subsequent costs incurred together totaling $117,643.

The Company entered into an Employment Agreement dated
March 20,2000 with its President and Chairman of the
Board of Directors. The Agreement is for a term of
five years and renewable by the Company. Under the
Agreement, the Company agrees to pay the following amounts:

- a) $50,000 per month net of all taxes;
- b) Use of a motor vehicle at the choice of the employee;
- c) Use of residential facilities in the Fort Myers
      area at a rental not to exceed $36,000 per annum;
- d) The Company will establish a performance related
      share option program, under which the Company's
      board of directors will determine participation
      commensurate with the employee's position. However,
      as of balance sheet date, the Company has not
      officially established a share option plan.

No payments have been made under the Agreement as of
the date of the financial statements but the $600,000
salary due has been accrued.

The Company entered into a three year equipment lease,
dated May 1,2000, with the principal shareholder, the
terms of which are discussed in Note 8.


NOTE 3 - RISKS AND UNCERTAINTIES

The Company's future operating results may be affected
by a number of factors.  The ability of the Company to
raise the capital necessary to continue to develop
and bring its products to market is not assured. The
products being  developed by PVAXX will be sold in a
highly competitive global market in which it
will need to demonstrate performance characteristics
sought by customers, at a  competitive price which
will yield a profit after production and distribution
costs. Estimates of the size of the market, and the
Company's eventual market  share may not be realized,
and the effect of competition cannot be determined.

The Company seeks to protect its intellectual
property rights by applying for patents and
registering its trademarks throughout the world.
However there can be no assurance that these will
adequately protect the Company.

The Company is dependant on highly skilled personnel.
The Company cannot guarantee their continued service
but seeks to mitigate the potential financial loss caused
by death by insuring the lives of its inventors for the
benefit of the Company.

NOTE 4 - COMMITMENTS AND CONTINGENT LIABILITIES (see Note 8 also)

Leased Facilities - Operating Leases

The Company has entered into a three (3) year operating
lease for office space in the Fort Myers area, Florida,
U.S.A., with an unrelated party. Under the terms of this
lease, effective June 1, 2000 the Company is obligated for
monthly base rental amounts plus sales tax and Common Area
Maintenance (CAM) charges. Under the terms of the lease,
the Company is obligated to keep and maintain the leased
premises, including fixtures and improvements, in good
condition. The Company has sub-let the property, with effect
from November 2000, through to the end of the lease
in May 2003, and the sub-tenant is responsible for all
costs until that time.

The Company's U.K. research and development facilities
are based in a property leased from an unrelated party.
The lease, completed July 20,2000, is for a period of 20
years from March 25,2000, with a break clause at the end of
the 10th year. The rent payable is to be reviewed every
5 years. In addition to the rental payments, the Company
is obliged, at its own cost, to insure and maintain the
property.

Future minimum lease payments under non-cancelable
operating leases are: $111,103; $113,792; $66,426;
$56,880; $56,880 for the 12 months ended March 31,2002,
2003, 2004, 2005 and 2006 respectively, and $227,520 for
subsequent years.

Rental expense under operating leases was $78,630 in the
9 months ended March 31,2001.

Employee Compensation

In addition to the employment contract with the President
disclosed in Note 2, an arrangement with the Vice-president
provides for a salary of $10,000 monthly for one year, and
$15,000 thereafter.


NOTE 5 - RESTRICTED CASH

On April 4, 2000, the former PVAXX executed an agreement
with an unrelated individual who transferred $299,970 to
an escrow agent in exchange for a 90,000 share block of
the 20,000,000 shares of common stock issued as discussed
in Notes 1 and 2. Under the terms of the escrow agreement,
updated and re-signed on April 24, 2001, the funds will
be released to the Company when the exchanged shares of
the new PVAXX Corporation are tradable on a U.S. national
exchange at not less than $5.00 per share. If this is not
achieved, the funds  may be released to the investor on
May 1, 2002, or such later date as the investor shall
determine, upon return of the 90,000 shares which would
then be  held as treasury stock. As of balance sheet date
the 90,000 shares of stock as well as the $299,970 remain
in the custody of the escrow agent


NOTE 6 - FAIR VALUES OF FINANCIAL INSTRUMENTS

The carrying amounts reported in the consolidated balance
sheet for cash and cash equivalents, restricted cash,
receivables, accounts payable, accrued  expenses and other
liabilities, approximate fair value because of immediate
or short-term maturity of these financial instruments. The
underlying carrying amount reported for long-term debt and
capital leases approximates fair value because, in general,
the interest on the underlying instruments fluctuates with
market rates.


NOTE 7 - LOSS PER SHARE

Basic net loss per common share is based on the
weighted average number of common shares outstanding
during each period presented. Convertible securities
are included as common stock equivalents only when
dilutive. Potential common stock equivalents totaling
10,000,000 shares have been excluded from dilutive loss
per share as the effects of such shares would have been
anti-dilutive.


NOTE 8 - LONG TERM LIABILITIES AND CAPITAL LEASES

Long-term liabilities include a three-year capital lease
dated May 1, 2000 with the majority shareholder, a
company owned and controlled by the President and Chairman
of the Board of Directors. The lease is for machinery,
equipment, and office furniture. The terms of the lease
require the Company to pay $11,729 per month as adjusted
for foreign currency, including interest of 2.5% plus a
balloon payment for the balance at the end of the term.
At the end of the term, PVAXX will own the leased assets.
The assets have been valued at an amount no greater than
their adjusted historical cost. The lease does not
require the Company to restrict its dividends, additional
debt, or further leasing. These lease terms have been
deemed to be comparable with similar arrangements with
unrelated parties.

The automobile capital lease is with an unrelated party.
Depreciation expense for leased assets is included in
depreciation expense for owned assets (see Note 9).

The gross amounts of assets recorded under capital
leases are listed in Note 9 at currency rates in effect
at the time of the transactions.

<TABLE>
<CAPTION>

Minimum future lease payments and present values of the
net minimum lease payments, at March 31,2001 exchange
rates, are as follows:

                                               Related Party      Third Party

<S>                                            <C>                <C>
12 months ended March 31
      2002                                         $ 140,752         $  3,491
      2003                                           140,752            2,328
      2004                                           224,988                -
                                                   ---------         --------
Total minimum lease payments                         506,492            5,819
Less: Imputed interest                                32,577            1,237
                                                   ---------         --------
Present value of net minimum
        lease payments                             $ 473,915         $  4,582
                                                   ---------         --------

      Current                                        125,115            2,749
      Long term                                      348,800            1,833
                                                   ---------         --------

      Total                                        $ 473,915         $  4,582
                                                   ---------         --------

PVAXX Corporation is the guarantor of these leases.

</TABLE>

NOTE 9 - PROPERTY, PLANT & EQUIPMENT

<TABLE>
<CAPTION>


                                             Total        Leased   Purchased

<S>                                        <C>           <C>        <C>
Leasehold property improvements             35,206        35,206           -
Machinery & equipment                      656,313       587,485      68,828
Office furniture & equipment                58,253        45,823      12,430
Motor vehicles                              15,044        12,775       2,269
                                           -------       -------      ------
Cost                                       764,816       681,289      83,527
Accumulated depreciation                  (135,049)     (123,502)    (11,547)
                                           -------       -------      ------
Net book value                            $629,767      $557,787     $71,980
                                           -------       -------      ------

</TABLE>

NOTE 10 - INCOME TAXES

The estimated tax benefits of the net operating loss carried
forward (sourced from both US and UK operations), and valuation
allowance made, are as follows:

                                                                   Tax asset

Net operating loss                                                 $ 636,000
Valuation allowance                                                 (636,000)
                                                                   ---------
Balance at March 31,2001                                           $       -
                                                                   ---------

ITEM 2.               MANAGEMENT'S DISCUSSION AND ANALYSIS OF
               FINANCIAL CONDITION, RESULTS, AND PLAN OF OPERATIONS

                      =====================================
                          PERIOD ENDING MARCH 31, 2001
                      =====================================

Except for historical information, the discussion in this Form 10-QSB contains
forward-looking statements that involve risks and uncertainties. These
statements may refer to the Company's future plans, objectives, expectations
and intentions. These statements may be identified by the use of words such as
"expect", "anticipate", "believe", "intend", "plan" and similar expressions.

The Company's actual results could differ materially from those anticipated in
such forward-looking statements. Factors that could contribute to these
differences include, but are not limited to, the risks discussed in the
section titled "Market Risks and other Business Factors" later in this Form
10-QSB.

Operations

The Company produces PVAXX(R), a polymer that may be used by various
manufacturers in producing agricultural, household, industrial, leisure and
medical market products.  In addition, the Company is researching and
developing other environmentally neutral products for use in manufacturing
processes.

The Company and its President have spent the past several years developing
PVAXX(R) and related technology and the Company is now selling small
quantities of PVAXX(R) for evaluation by customers who could potentially
order significant quantities, operating in the following industries:

- Pharmaceutical;
- Industrial;
- Retail;
- Household;
- Agricultural;
- Leisure.

At present, the Company does not intend to acquire or invest in any
complimentary businesses.

Period ended March 31,2001

The Company has accomplished the following during the period from inception
on March 16,2000 to March 31,2001:

- has opened a new research & development facility and European HQ in
  Kemble, UK;
- has sold small quantities of product to customers that could potentially
  order significant amounts of PVAXX(R) for use in manufacturing various
  plastic products in the industries listed above;
- has commenced a marketing program;
- has appointed several members of a management team for sales & marketing;
  production & engineering; and a Chief Financial Officer;
- has appointed Nadeau & Simmons as corporate legal advisors; and
- has registered the Company to do business in Dubai, United Arab Emirates,
  where it presently has an option to establish a manufacturing
  facility.

During this period of time, the company has been financed, by loan and lease
facilities, by its principal shareholder.

The next twelve months

The Company plans to develop its business model in order to maximize its
earnings potential. The Company's business model is based on its belief that
its strength is the invention of new products and processes to produce
materials which are not harmful to humans and their environment. Currently
the Company does not have the resources to manufacture large quantities of
its products. The Company believes that the best way to make large
quantities of its materials is to arrange for third party companies, with
the resources, to manufacture their own-label BioCompostable(TM) products,
under license from the Company. Similarly, the Company plans to have its
patented process equipment manufactured under license from the Company.  A
number of companies, both existing and potential customers, have expressed
an interest in using PVAXX(R) to make products that currently utilize
plastic materials. In order to plan operations more effectively, the Company
is currently obtaining "memorandums of understanding" so as to indicate both
the timing of orders and the quantities envisaged. The Company then plans to
use these in its discussions with manufacturing companies. A number of
manufacturing companies have expressed their interest in this concept.
Similarly, a number of engineering companies have expressed an interest in
making the Company's tablet forming and pelletizing equipment.  The
principal objective for the next twelve months is to have signed sales
contracts in place -the Company plans to have a number of these in place
before the end of calendar 2001 - and commence production of large volumes
of its products.

If the Company is unsuccessful in persuading specialist manufacturing
companies to undertake large scale production, then the Company plans to
increase its own production facilities.

During the last 12 months, since inception, we have focused on the uses and
disposal of plastic. We have completed the necessary research and
development to establish several grades of our product which are suitable
for the manufacture of plastic film, extruded and molded plastic products.
The company makes samples of finished products that potential customers can
manufacture using PVAXX(R). The company provides such product samples along
with technical specifications of PVAXX(R) to potential customers.  Small
quantities of PVAXX(R) polymers are being shipped in pellet form in 50 Kilo
drums to various customers who have the potential to order significant
quantities. These shipments are purchased by the customer at market prices,
but are primarily used by the buyers to evaluate the functionality and
durability of PVAXX(R). Prospective customers are responsible for completing
their own trials and tests to determine whether PVAXX(R) will be suitable
for the manufacture of their products. However the company offers the
technical expertise of its officers and staff to customers to ensure proper
evaluation. These trials and tests take a number of months to complete
particularly if the customer wishes to ensure the life expectancy of the
product, its biodegradability and compostability. If suitable for the
customer's process, PVAXX(R) may be used to enable customers in a range of
industries to make products such as film, sheet, wrapping and packaging
materials, fibers and moldings that will have no toxic effects on the
environment at an affordable cost. This approach is expected to lead to the
completion of "memorandums of understanding" with major customers to
indicate likely volumes and the timing of these requirements.

The company has successfully engineered and patented machinery to produce
pellets of PVAXX(R). The company's current facilities are capable of
producing about 8,000 tons per annum.  The company has taken an option to
acquire land in Dubai, United Arab Emirates, which could enable the company
to construct additional facilities to produce approximately 100,000 tons
per annum. As investment will be required to install facilities to enable
production from this site, a decision on whether to go ahead or not will
depend on the outcome of the Company's offering and discussions of other
options, such as arranging for PVA manufacturers to produce the Company's
BioCompostable(TM) materials.

Independent research has indicated that the potential market size for our
products could be 30 million tons per annum. Interest in our products from
around the world has been created by our marketing programme and indicates a
global demand which may become significant.

In order to exploit this opportunity as soon as possible, the company's
management believes that it should consider licensing the production of its
polymers. Consequently negotiations are currently taking place with a number
of PVA manufacturers to produce biodegradable polymers from the patented
compositions of ingredients that the company would sell licenses to them.
These companies should also be able to utilize their own world-wide
distribution partners to provide the geographical reach and market knowledge
necessary to ensure maximum exposure.

The company is currently working with Mitsui Plastics, a major international
distributor, evaluating opportunities for its products in the U.S.A., which
is seen by Management as a significant potential market. If substantial
contracts could be obtained, this would provide a greater incentive to PVA
manufacturers to commence production.

We anticipate a proportion of the initial sales to customers will be to the
Italian market, where new legislation to ban a number of plastic applications
is currently in the implementation phase. We are currently working with a
development partner in this market for whom we have successfully made a
stick for their use in making a healthcare product. Working with a
development partner in each market sector (i.e. pharmaceuticals,
agriculture, etc.) is viewed as another way to exploit our product's
potential as soon as possible. The company is currently working with a
number of potential customers who could receive products produced from the
first large deliveries of PVAXX(R). The pharmaceutical sector is being
developed over the mid-term and will offer higher-margin opportunities.

In addition the Company is considering the manufacture of its patented
pellet-forming machinery under license by specialist engineering companies
in order that greater quantities of our products could be produced more
quickly. The Company is currently in discussions with a company for this
purpose.

Overhead and Operating Expenses

Currently we do not expect our present levels of administration expense
(about $400,000 per quarter), nor our research and development activities
(which cost about $300,000 per quarter) to increase significantly. Further
increases in costs will be determined by increasing production activities.

Liquidity and Capital Resources

The Company remains in the development stage and, since inception, has
experienced no significant change in liquidity or capital resources or
stockholder's equity.  The Company's balance sheet as of March 31, 2001,
reflects a current asset value of $369,476, and a total asset value of
$1,121,235 in the form of cash; property, plant and equipment (primarily
leased); and costs of applying for patent protection.
Prior to achieving greater levels of sales, the majority shareholder has
provided additional loan finance to the Company and may contribute
additional funds, or the Company may be successful in raising capital
through the sale of equity. The Company is in the process of registering for
the sale of equity in connection with the sale of 1,200,000 shares at
approximately $10.00/share. The Company does not have any underwriting
commitments for such sale of equity and cannot provide assurances that it
will raise significant proceeds from this offering and may receive no or
nominal proceeds, significantly restricting the Company's activities and
plan of operations.

Notwithstanding the steps taken by us to raise additional capital, our
immediate cash requirements are significant. We cannot be sure that we will
be able to successfully realize cash flow from operations or that such
cash flow will be sufficient. However, we believe that our existing and
anticipated capital resources will enable us to fund our planned operations
through Fiscal 2001 and into fiscal 2002.

In addition, our annual and quarterly operating results may be
affected by a number of factors, including the following:

- our ability to manage inventories, shortages of components or labor;
- the degree of automation used in the assembly process;
- fluctuations in material costs and the mix of material costs versus labor;
- manufacturing and overhead costs;
- price competition;
- the inability to pass on excess costs to customers;
- the timing of expenditures in anticipation of increased sales; and
- customer product delivery requirements.

Any one of these factors, or a combination thereof, could adversely affect
us.

The Company believes that obtaining $1,000,000 of net proceeds from this
offering together with cash generated from planned operations will permit it
to continue meeting its working capital obligations and fund the further
development of its business for at least the next 12 months. There can be no
assurance that any additional financing will be available to the Company on
acceptable terms, or at all. If adequate funds are not available, the
Company may be required to delay, scale back or eliminate its research,
engineering and development or manufacturing programs or obtain funds
through arrangements with partners or others that may require the Company to
relinquish rights to certain of its technologies or potential products or
other assets. Accordingly, the inability to obtain such financing could have
a material adverse effect on the Company's business, financial condition and
results of operations.

Evolving Industry Standards; Rapid Technological Changes

The Company's success in its business will depend in part upon its continued
ability to enhance its existing products, to introduce new products quickly
and cost effectively to meet evolving customer needs, to achieve market
acceptance for new product offerings and to respond to emerging industry
standards and other technological changes. There can be no assurance that the
Company will be able to respond effectively to technological changes or new
industry standards.  Moreover, there can be no assurance that competitors of
the Company will not develop competitive products, or that any such
competitive products will not have an adverse effect upon the Company's
operating results.

There can also be no assurance that the Company will be successful in
refining, enhancing and developing its operating strategies and products
going forward, that the costs associated with refining, enhancing and
developing such strategies and products will not increase significantly in
future periods or that the Company's existing technology will not become
obsolete as a result of ongoing technological developments in the
marketplace.

Volatility of Stock Price

The Company believes factors such as the Company's liquidity and financial
resources, quarter to quarter and year-to-year variations in financial
results could cause the market price of the Company's common stock to
fluctuate substantially. Any adverse announcement with respect to such
matters or any shortfall in revenue or earnings from levels expected by
management could have an immediate and material adverse effect on the trading
price of the Company's common stock in any given period. As a result, the
market for the Company's common stock may experience material adverse price
and volume fluctuations and an investment in the Company's common stock is
not suitable for any investor who is unwilling to assume the risk associated
with any such price and volume fluctuations. As a consequence this may
inhibit the Company's ability to raise additional finance, if required.

Sufficiency of Cash Flows

The Company believes that current cash balances and any cash generated from
operations and from available debt or equity financing will be sufficient to
meet its cash needs for working capital and capital expenditures for at least
the next twelve months provided at least $1,000,000 is raised in this
offering. Thereafter, if cash generated from operations is insufficient to
satisfy the Company's liquidity requirements, management may seek to sell
additional equity or obtain credit facilities. The sale of additional equity
could result in additional dilution to the Company's shareholders.

Results of Operations

Although we have yet to realize significant revenues from our planned
operations, sales of small quantities of product, for trialing and testing
purposes, have resulted in revenues of $3,699 being received by the Company
through March 31, 2001.  The operating losses for the quarter ended March
31,2001 are beneficially affected by the inclusion of an adjustment arising
from an over-accrual of costs of about $390,000 as at December 31,2000.

Income Taxes

The Company accounts for income taxes in accordance with Statement of
Financial Accounting Standards No. 109, "Accounting for Income Taxes" issued
by the Financial Accounting Standards Board, under which deferred tax assets
and liabilities are provided on differences between the carrying amounts for
financial reporting and the tax basis of assets and liabilities for
income tax purposes using the enacted tax rates.  Under SFAS 109, deferred
tax assets may be recognized for temporary differences that will result in
deductible amounts in future periods. A valuation allowance is recognized if
on the weight of available evidence it is more likely than not that some
portion or the entire deferred tax asset will not be realized. Consequently
the Company has not recorded an asset on its balance sheet to recognize the
tax benefit of its losses since inception.


                          PART II  OTHER INFORMATION

ITEM 1.  Legal Proceedings

          Neither the Registrant nor any of its affiliates are a
          party, nor is any of their property subject, to material
          pending legal proceedings or material proceedings known
          to be contemplated by governmental authorities.


ITEM 2.  Changes in Securities

          None


ITEM 3.  Defaults Upon Senior Securities

          None


ITEM 4.  Submission of Matters to a Vote of Security Holders

          None

ITEM 5.  Other Information

          None

ITEM 6.  Exhibits and Reports on Form 8 K

         a.  Exhibits



         b.  Reports on Form 8 K

             None

<PAGE>  17

INDEX TO EXHIBITS

<TABLE>
<CAPTION>

EXHIBIT      NO      DESCRIPTION

<S>          <C>     <C>


#            3.1     Articles of Incorporation of the Registrant, as amended;

#            3.2     Bylaws of the Registrant;

#            4.1     Instruments Defining Rights of Security Holders/Minutes
                     of Annual/Special Meetings of the Registrant;

#           10.1     Issuance of Restricted Shares from Authorized Shares

#           23.1     Consent of Mark T. Thatcher, P.C.;

#           99.1     Safe Harbor Compliance Statement

_______________________
x     Filed herewith.

#     Incorporated by reference from the Registrant's Amendment No. 2 to the
      Registration Statement filed on Form 10-SB on or about May 14, 1999.


</TABLE>
                                   SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                           PVAXX CORPORATION and
                                           OAK BROOK CAPITAL IV, INC.

                                           /s/ Nadeau & Simmons, P.C.

DATE:  January 7, 2002                     By: NADEAU & SIMMONS, P.C.
                                           Title: Filing Agent